Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
51 hedge funds and large institutions have $147M invested in Agile Therapeutics in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
38% more funds holding
Funds holding: 37 → 51 (+14)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $154M → $147M (-$6.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.83M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.67M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$832K |
| 4 |
State Street
Boston,
Massachusetts
|
+$640K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$597K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$4.37M |
| 2 |
RA
Royce & Associates
New York
|
-$1.69M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.52M |
| 4 |
DM
Deerfield Management
New York
|
-$973K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$253K |
AGRX Hedge Fund Activity: Q2 2015 in Review
51 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2015, worth a combined $147M — down 4.1% from $154M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AGRX positions and 5 closed out — a net gain of 14 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $6.83M. The largest seller was Foresite Capital Management II, cutting an estimated $4.37M.
- 51 institutional investors held Agile Therapeutics (AGRX) as of Q2 2015, up from 37 in Q1 2015.
- Funds reported $147M of Agile Therapeutics stock for Q2 2015, down 4.1% quarter-over-quarter.
- 19 funds opened new Agile Therapeutics positions in Q2 2015 and 5 closed out, a net change of +14 holders.
- The largest Agile Therapeutics buyer in Q2 2015 was Invesco, an estimated $6.83M added.
- The largest Agile Therapeutics seller in Q2 2015 was Foresite Capital Management II, an estimated $4.37M sold.
Based on aggregated 13F filings for Q2 2015.